Literature DB >> 17496720

Depression-free day to utility-weighted score: is it valid?

Jeffrey M Pyne1, Shanti Tripathi, D Keith Williams, John Fortney.   

Abstract

BACKGROUND: Cost-utility analyses using formulas to convert depression-free days (DFDs) to utility-weighted scores are increasingly common. These formulas are based on linear extrapolation of data documenting the correlation between depression symptom severity and generic health-related quality of life.
OBJECTIVE: We sought to examine the validity of formulas converting DFDs to utility weights.
METHODS: We undertook an observational study with data collection at baseline, 1 week and 1, 3, 6, 9, and 12 months on 77 subjects (42 inpatient, 35 outpatient) diagnosed with current major depression. Subjects were divided into treatment response categories based on changes in depression severity. Depression severity measures used were the Hamilton Rating Scale for Depression (HAM-17) and Beck Depression Inventory (BDI) and the health-related quality of life measure was the self-administered Quality of Well-Being scale (QWB-SA). DFD calculations were based on depression severity scores and converted to utility weights using available formulas. Utility-weighted data collected over the course of 1 year were used to estimate quality-adjusted life years (QALYs).
RESULTS: QALYs estimated from the QWB-SA were significantly lower than those based on utility-weighted DFD calculations but the incremental QALYs were not significantly different. Using a slightly lower utility-weighted conversion factor for the BDI or a larger BDI severity range to calculate DFDs resulted in a better fit compared with the QWB-SA.
CONCLUSIONS: Our results support the validity of the existing HAM-17 utility-weighted formula and suggest modifications for the BDI formula. If generic health-related quality of life measures are not available for conducting cost-utility analyses of depression interventions then the existing HAM-17 and modified BDI formulas appear to be reasonable alternatives.

Entities:  

Mesh:

Year:  2007        PMID: 17496720     DOI: 10.1097/01.mlr.0000256971.81184.aa

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  10 in total

1.  Population-level cost-effectiveness of implementing evidence-based practices into routine care.

Authors:  John C Fortney; Jeffrey M Pyne; James F Burgess
Journal:  Health Serv Res       Date:  2014-10-18       Impact factor: 3.402

2.  Association of Increased Chronicity of Depression With HIV Appointment Attendance, Treatment Failure, and Mortality Among HIV-Infected Adults in the United States.

Authors:  Brian W Pence; Jon C Mills; Angela M Bengtson; Bradley N Gaynes; Tiffany L Breger; Robert L Cook; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Michael J Mugavero
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

3.  The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial.

Authors:  Brian W Pence; Bradley N Gaynes; Julie L Adams; Nathan M Thielman; Amy D Heine; Michael J Mugavero; Teena McGuinness; James L Raper; James H Willig; Kristen G Shirey; Michelle Ogle; Elizabeth L Turner; E Byrd Quinlivan
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

4.  Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.

Authors:  Frances L Lynch; John F Dickerson; Greg Clarke; Benedetto Vitiello; Giovanna Porta; Karen D Wagner; Graham Emslie; Joan Rosenbaum Asarnow; Martin B Keller; Boris Birmaher; Neal D Ryan; Betsy Kennard; Taryn Mayes; Lynn DeBar; James T McCracken; Michael Strober; Robert L Suddath; Anthony Spirito; Matthew Onorato; Jamie Zelazny; Satish Iyengar; David Brent
Journal:  Arch Gen Psychiatry       Date:  2011-03

5.  Advantages of using estimated depression-free days for evaluating treatment efficacy.

Authors:  Steven D Vannoy; Patricia Arean; Jürgen Unützer
Journal:  Psychiatr Serv       Date:  2010-02       Impact factor: 3.084

6.  The cost-effectiveness of depression treatment for co-occurring disorders: a clinical trial.

Authors:  Katherine E Watkins; Alison E Cuellar; Kimberly A Hepner; Sarah B Hunter; Susan M Paddock; Brett A Ewing; Erin de la Cruz
Journal:  J Subst Abuse Treat       Date:  2013-10-02

7.  How bad is depression? Preference score estimates from depressed patients and the general population.

Authors:  Jeffrey M Pyne; John C Fortney; Shanti Tripathi; David Feeny; Peter Ubel; John Brazier
Journal:  Health Serv Res       Date:  2009-04-21       Impact factor: 3.402

8.  Cumulative Burden of Depression and All-Cause Mortality in Women Living With Human Immunodeficiency Virus.

Authors:  Jon C Mills; Brian W Pence; Jonathan V Todd; Angela M Bengtson; Tiffany L Breger; Andrew Edmonds; Robert L Cook; Adebola Adedimeji; Rebecca M Schwartz; Seble Kassaye; Joel Milam; Jennifer Cocohoba; Mardge Cohen; Elizabeth Golub; Gretchen Neigh; Margaret Fischl; Mirjam-Colette Kempf; Adaora A Adimora
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

9.  The Sub-Saharan Africa Regional Partnership (SHARP) for Mental Health Capacity-Building Scale-Up Trial: Study Design and Protocol.

Authors:  Bradley N Gaynes; Christopher F Akiba; Mina C Hosseinipour; Kazione Kulisewa; Alemayehu Amberbir; Michael Udedi; Chifundo C Zimba; Jones K Masiye; Mia Crampin; Ishmael Amarreh; Brian W Pence
Journal:  Psychiatr Serv       Date:  2020-12-09       Impact factor: 4.157

10.  Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial.

Authors:  Shinji Shimodera; Toshi A Furukawa; Yoshio Mino; Kae Shimazu; Atsushi Nishida; Shimpei Inoue
Journal:  BMC Psychiatry       Date:  2012-05-14       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.